This study confirms the inefficiency of HMM-CAF as second-line chemotherapy; cisplatin-CAF is also not recommended in patients previously treated with multidrug therapy because the very low response is outweighed by severe toxicity. In general, these conclusions agree with previous failures reported as second-line chemotherapy for ovarian cancer.
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|Publication status||Published - 1982|
ASJC Scopus subject areas
- Cancer Research